Abstract Library

#4181 High prevalence of deficiencies in fat-soluble vitamins, minerals and trace elements but no relation with malnutrition in patients with gastroenteropancreatic neuroendocrine tumors using somatostatin analogues

Introduction: Since 2019 the Global Leadership Into Malnutrition (GLIM) criteria exist for diagnosing malnutrition. Patients (pts) with gastoenteropancreatic (GEP) neuroendocrine tumors (NETs) treated with somatostatin analogues (SSAs) are at risk of malnutrition. Deficiencies in fat-soluble vitamins, minerals and trace elements (micronutrients) are not part of the GLIM criteria but frequently reported in pts with GEP-NETs treated with SSAs.

Conference:

Presenting Author: Clement D

Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,

Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,

#3308 Hypovitaminosis D in patients with neuroendocrine tumors undergoing SSA therapy

Introduction: Neuroendocrine tumors of the gastrointestinal tract are rare tumors representing a heterogeneous group of tumors. Somatostatin analogues are commonly used in the treatment of gastroeenteropancreatic neuroendocrine tumors.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Nosakova L

Authors: Nosakova L, Bánovčin P, Uhrík P, Pindura M, Hyrdel R,

Keywords: neuroendocrine tumor, somatostatin analogues, hypovitaminosis D,

#2772 Vitamin Supplementation and a Personalized Diet in Patients with Neuroendocrine Tumors: The DIVIT Study

Introduction: Patients with neuroendocrine tumors (NETs) are at risk for vitamin deficiencies and poor nutritional status due to excessive serotonin production, diarrhea, previous gastrointestinal surgery, and/or treatment with somatostatin analogues (SSA). Little knowledge exists about vitamin deficiency and how patients should be supported for the deficiencies they develop during their long-lasting disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Stelwagen J

Authors: Stelwagen J, de Hosson L, Sijtema B, van Faassen M, Kema I,

Keywords: Vitamins, nutritional support, supplementation, vitamin deficiency, single-arm intervention,

#2147 Nutritional Assessment and Vitamin Deficiencies in Patients with NETs

Introduction: As a result of disease or related to its management, patients with neuroendocrine tumours may have altered gut or pancreatic function that can cause nutritional deficiencies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Lim S, Reynolds M, Rees D, Chaudhry R, Blackhouse J,

Keywords: Nutrition, Dietetics, Malnutrition, Vitamin Deficiency, Screening,

#2078 Self-Reported Side Effects in Neuroendocrine Tumor (NET) Patients Prescribed Somatostatin Analogues – The Role for Specialist Dietitians and Nurses

Introduction: In practice, many patients with NETs report a change in symptoms after starting somatostatin analogues (SSA’s). Many health professionals and NET patient advocates have noticed that some of the side effects experienced by patients are more common than patient information literature suggests. It is therefore important to ask what and how severe experiences are, and compare to literature, to help raise awareness amongst NET health professionals.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Whyand T, Davies P, Bouvier C,

Keywords: B12, SSA, Side effects, Fat soluble vitamins,